Encompass Health (NYSE:EHC) EVP John Patrick Darby Sells 4,858 Shares

Encompass Health Corporation (NYSE:EHC) EVP John Patrick Darby sold 4,858 shares of the business’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $121.09, for a total value of $588,255.22. Following the sale, the executive vice president owned 75,041 shares in the company, valued at approximately $9,086,714.69. The trade was a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

John Patrick Darby also recently made the following trade(s):

• On Monday, August 10th, John Patrick Darby sold 8,906 shares of Encompass Health stock. The stock was sold at an average price of $125.95, for a total value of $1,121,710.70.

Encompass Health Price Performance

Encompass Health stock opened at $122.23 on Wednesday. The firm has a market capitalization of $12.06 billion, a PE ratio of 19.91, a P/E/G ratio of 2.43 and a beta of 0.74. Encompass Health Corporation has a 52 week low of $92.77 and a 52 week high of $127.99. The firm’s 50-day simple moving average is $114.08 and its 200 day simple moving average is $107.33. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC) last posted its earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the firm posted $1.40 EPS. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. On average, equities research analysts predict that Encompass Health Corporation will post 6.08 EPS for the current fiscal year.

Encompass Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be given a dividend of $0.21 per share. The ex-dividend date is Thursday, October 1st. This represents a $0.84 annualized dividend and a dividend yield of 0.7%. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. Encompass Health’s payout ratio is presently 12.38%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. lifted its position in Encompass Health by 3,059,159.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after buying an additional 3,793,358 shares during the period. AlphaCore Capital LLC purchased a new stake in Encompass Health in the 4th quarter valued at about $4,881,000. Ancora Advisors LLC acquired a new position in shares of Encompass Health during the 2nd quarter valued at about $10,639,000. Systematic Financial Management LP lifted its holdings in shares of Encompass Health by 3.6% during the 4th quarter. Systematic Financial Management LP now owns 440,752 shares of the company’s stock worth $46,782,000 after acquiring an additional 15,462 shares during the period. Finally, Trillium Asset Management LLC lifted its holdings in shares of Encompass Health by 5.7% during the 4th quarter. Trillium Asset Management LLC now owns 217,734 shares of the company’s stock worth $23,424,000 after acquiring an additional 11,793 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EHC. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a report on Sunday, August 16th. Weiss Ratings upgraded Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Truist Financial increased their price objective on Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, August 7th. UBS Group lifted their price objective on Encompass Health from $150.00 to $155.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, TD Cowen upped their target price on shares of Encompass Health from $125.00 to $140.00 and gave the company a “buy” rating in a report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $148.71.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.